Healthy Elderly Male
Conditions
Brief summary
A phase 1 study of E2022 tape formulation in healthy elderly males to evaluate the safety and pharmacokinetics.
Interventions
DRUGE2022 Tape Formulation
E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
Sponsors
Eisai Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Male non-smokers (not smoking at least 4 weeks before Period 1) aged 65 years or older at informed consent 2. BMI at screening is 18.5 kg/m2 or above - below 28.0 kg/m2 3. Written informed consent 4. Given full explanation of this study and is willing to and able to comply with the protocol requirements
Exclusion criteria
1. Have a current or past history of disorder requiring medical treatment within 8 weeks before the first application or infection within 4 weeks before the first application 2. Have a disorder within 4 weeks before the first application which affects the evaluation of study drug such as psychiatric, gastrointestinal, hepatic, renal, respiratory, endocrinological, hematological, neurological or cardiovascular system, or congenital metabolic abnormality 3. Have a history of gastrointestinal surgery (e.g., liver, kidney, digestive tract) which affects the pharmacokinetics of study drug, 4. Have a history of treatment-requiring drug or food allergy or seasonal allergy at screening 5. Had caffeine-containing food or drink or alcohol within 72 hours before study drug application in Period I 6. Had nutritional supplements, herbal preparations (including oriental medicines) or others (e.g., grapefruit-containing food or beverage) which may affect drug metabolizing enzymes and transporters, within 1 weeks before Period I 7. Have used liquid products (including cosmetics) on study application sites (back, upper limb, chest), patch, tape or bandage, within 4 weeks before Period 1 8. Present or past clinical signs of skin hypersensitivity to topical product or atopic dermatitis 9. Excessively hairy or have shaved at application sites (back, upper limb, chest) within 4 weeks before Period 1 10. Eczema, dermatitis, abnormal pigmentation, injury, or scar at application sites which may affect the evaluation of skin symptoms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number and frequency of adverse events | 168 hours after the end of application |
Secondary
| Measure | Time frame |
|---|---|
| Maximal Drug Concentration (CMax) | 216 hours after the end of application |
| Area Under the Plasma Concentration-Time Curve (AUC) | 216 hours after the end of application |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 216 hours after the end of application |
| Plasma Decay Half-Life (t1/2) | 216 hours after the end of application |
Countries
Japan
Outcome results
None listed